ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
70 participants
Dec 19, 2025
OBSERVATIONAL
Conditions
Summary
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Eligibility
Inclusion Criteria3
- Is at least 18 years of age and the local legal age of consent for clinical studies
- Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
- If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening
Exclusion Criteria2
- Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
- Is MGFA (Myasthenia Gravis Foundation of America) Class V
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous infusion of efgartigimod
Intravenous infusion of empasiprubart
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07294170